Biotech and Pharma
Freya Biosciences, established in 2020 with the collaboration of leading experts in women’s health and reproductive immunology, is a pioneering biotech company headquartered in Copenhagen, Denmark. Freya Biosciences is devoted to transforming the landscape of women’s reproductive health through the development of groundbreaking microbial immunotherapies. Freya Biosciences’ primary focus lies in addressing the complex challenges of infertility, a condition affecting millions of women globally.
Indaco has participated in Freya Biosciences’ Series A funding round of $38 million, led by Sofinnova Partners and OMX Ventures, and supported by a consortium of global investors, including The Export and Investment Fund of Denmark, Angelini Ventures, Mike Jafar Family Office, CE-Ventures, Corundum Systems Biology. This investment will accelerate the clinical development of Freya Biosciences’ lead drug candidate and expand the research into other reproductive health conditions.
Indaco Bio Fund invested into Freya Biosciences in December 2023.